A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.
Latest Information Update: 21 Jul 2016
At a glance
- Drugs Octreotide (Primary)
- Indications Diarrhoea
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sandoz
- 21 Jul 2016 New trial record